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It has been shown that glucocorticoids reduce the hearing threshold shifts associated with cochlear
implantation. Previous studies evaluated the administration of glucocorticoids immediately before sur-
gery or the repeated pre- or perioperative systemic application of glucocorticoids. The aim of this study
was to evaluate the effects of a sustained release dexamethasone hydrogel in hearing preservation
cochlear implantation. To address this issue, a guinea pig model of cochlear implantation was used. 30
normal hearing pigmented guinea pigs were randomized into a group receiving a single dose of a
dexamethasone/poloxamer407 hydrogel one day prior to surgery, a second group receiving the hydrogel
seven days prior to surgery and a control group. A silicone cochlear implant electrode designed for the
use in guinea pigs was inserted to a depth of 5 mm through a cochleostomy. Compound action potentials
of the auditory nerve (frequency range 0.5e32 kHz) were measured preoperatively, directly post-
operatively and on postoperative days 3, 7, 14, 21 and 28. Following the last audiometry, temporal bones
were harvested and histologically evaluated.
Dexamethasone hydrogel application one day prior to surgery resulted in signiﬁcantly reduced hearing
threshold shifts at low, middle and high frequencies measured at postoperative day 28 (p < 0.05).
Application of the hydrogel seven days prior to surgery did not show such an effect. Dexamethasone
application one day prior to surgery resulted in increased outer hair cell counts in the cochlear apex and
in reduced spiral ganglion cell counts in the basal and middle turn of the cochlea, a ﬁnding that was
associated with a higher rate of electrode translocation in this group.
In this study, we were able to demonstrate functional beneﬁts of a single preoperative intratympanic
application of a sustained release dexamethasone hydrogel in a guinea pig model of cochlear
implantation.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).; CAP, compound action po-
tic stimulation; EIT, electrode





r B.V. This is an open access article1. Introduction
Glucocorticoids (GCs) are used for the treatment of a variety of
conditions affecting the inner ear. Amongst others, the indications
for GCs in this setting include sudden sensorineural hearing loss,
Meniere's disease, cisplatin ototoxicity and autoimmune-mediated
hearing loss (Casani et al., 2012; Marshak et al., 2014; Rauch et al.,
2011; Trune and Canlon, 2012). Technical and surgical advances in
the ﬁeld of cochlear implantation (CI) resulted in an extension of
the indication criteria. Due to the audiological beneﬁts of electric-
acoustic stimulation (EAS), residual hearing preservation hasunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2010; Gantz et al., 2016; Gifford et al., 2013; von Ilberg et al.,
2011). Various electrode-related histological alterations, including
ﬁbrosis, fractures of the osseous spiral lamina or foreign body giant
cell inﬁltration have been described in the literature (O'Leary et al.,
2013). In addition to the direct surgical trauma caused by the
electrode, inﬂammation and the induction of apoptosis can result
in a further, delayed hearing loss (Eshraghi et al., 2013). Most of
these deleterious reactions are directly or indirectly affected by
GCs, which have therefore been extensively studied in the setting of
hearing preservation CI. In the guinea pig model, preoperative or
perioperative application of topical and systemic GCs has been
shown to reduce hearing threshold shifts (Chang et al., 2009;
Connolly et al., 2011; Eastwood et al., 2010; Kuthubutheen et al.,
2015; Lee et al., 2013; Maini et al., 2009; Quesnel et al., 2011).
Whilst extended preoperative systemic GCs have been demon-
strated to be effective in the prevention of hearing loss after CI
(Kuthubutheen et al., 2015), only short-term preoperative topical
application protocols have been evaluated so far (James et al.,
2008). This is at least partly due to the loss of ﬂuids through the
Eustachian tube, which makes prolonged and controlled topical
drug delivery to the inner ear challenging. Out of various studies
aiming at a sustained GC release to the inner ear (Barriat et al.,
2012; Borden et al., 2011; Plontke et al., 2009), the use of ther-
moreversible poloxamer407 (POX407) hydrogels has emerged as a
very promising approach (Honeder et al., 2014; Lambert et al.,
2012; Piu et al., 2011), which is currently also evaluated in clinical
studies. These gels can be injected into the middle ear in a ﬂuid
state at room temperature and turn into a hydrogel at body tem-
perature (Engleder et al., 2014). Also, intratympanic (IT) application
of POX407 hydrogels does not cause adverse effects except for a
transient conductive hearing loss (Honeder et al., 2014; Wang et al.,
2009). It has been shown that the IT application of POX407
hydrogels results in therapeutic GC levels in the inner ear for more
than ten days (Honeder et al., 2014; Piu et al., 2011), and that the IT
application of a dexamethasone/POX407 hydrogel leads to a
reduction of cisplatin-induced hearing loss in an animal model
(Fernandez et al., 2016). Even though our group failed to show
reduced hearing threshold shifts after the intraoperative applica-
tion of dexamethasone and triamcinolone-acetonide POX407
hydrogels (Honeder et al., 2015b), there is experimental evidence
pointing to a potentially higher efﬁcacy of preoperative application
protocols (Kuthubutheen et al., 2015). Most GC effects are caused by
the regulation of gene transcription via direct interaction of the GC
receptor with GC-responsive elements or via transactivation or
transrepression of other transcription factors (Kassel and Herrlich,
2007). Hoang et al. showed, that the upregulation of the anti-
apoptotic genes Bcl-2 and Bcl-xl in organ of Corti explants
required 48 h after exposure to dexamethasone (Hoang et al.,
2009). Furthermore, upregulation of Fkbp5, a protein involved in
immunosuppression and inhibition of apoptosis, was exclusively
described hours after GC application (Maeda et al., 2010, 2012).
Advantages of the POX407 hydrogel as compared to other delivery
protocols include its release proﬁle, which results in sustained
therapeutic GC perilymph levels after a single IT injection, and the
potential to translate this approach into clinical practice without
any expected major complications (Lambert et al., 2012; Piu et al.,
2011). An additional beneﬁt is that long-term release of GCs from
the round window niche reduces drug gradients in the perilymph
and thus results in higher drug concentrations in the apical parts of
the cochlea (Salt et al., 2011), which are of special interest in the
setting of hearing preservation CI.
Therefore, the aim of this study was to evaluate the preoperative
applicationofa6%dexamethasone/POX407hydrogelonedayorseven
days before surgery for otoprotective effects in an animalmodel for CI.2. Material and methods
All animal experiments were approved by the local animal
welfare committee and the Austrian Federal Ministry for Science,
Research and Economy (BMWF-66.009/0251-II/3b/2013).
2.1. Experimental groups
30 pigmented guinea pigs weighing between 697 and 970 g
were randomized into one of three groups, each consisting of 10
animals. The ﬁrst group received an IT injection of a thermorever-
sible dexamethasone hydrogel with extended release characteris-
tics one day prior to surgery (Dex d-1) and the second group
received the same hydrogel seven days before CI (Dex d-7). Animals
in the control group underwent CI after the application of 50 ml of
the control hydrogel (20% w/v POX407) one day or seven days prior
to surgery. As a previously published study using the same animal
model and delivery device did not show a protective effect of
intraoperative glucocorticoid hydrogel application, an intra-
operative administration group was not included into this study
(Honeder et al., 2015b).
2.2. Auditory testing
All audiometric measurements were performed in a soundproof
chamber (mac-2; Industrial Acoustics Company, Niederkrüchten,
Germany). A DT-48 loudspeaker (Beyerdynamic, Heilbronn, Ger-
many) was positioned 3 cm from the tested ear and a K2 micro-
phone (Sennheiser, Wedemark, Germany) was placed directly at
the level of the pinna for calibration. A wax earplug (Ohropax,
Werheim, Germany) was used to occlude the contralateral external
ear canal during auditory functional testing. A custom-made setup,
including a PC system equipped with a multifunction I/O card
(National Instruments, Austin, TX, USA) and AudiologyLab software
(Otoconsult, Frankfurt am Main, Germany), was used for the mea-
surement of auditory potentials. Stimuli for the determination of
auditory brainstem response (ABR) and compound action potential
(CAP) thresholds included clicks and tone bursts (3 ms duration;
1 ms rise/fall) presented in the frequency range of 0.5e32 kHz.
Signals were ampliﬁed (80 dB), band-pass ﬁltered (ABR: 10 Hz to
10 kHz; CAP: 200 Hz to 5 kHz) and averaged (512 or 32) for the
measurement of ABRs and CAPs, respectively. The digital sampling
rate for ABR and CAP measurements was 50 kHz. Click-ABR mea-
surements were performed approximately one week before CI to
guarantee normal hearing of the animals prior to study-inclusion.
Frequency-speciﬁc CAP thresholds were determined at three fre-
quencies per octave and in 5 dB steps directly before CI-electrode
insertion and immediately after surgery, as well as on post-
operative days 3, 7, 14, 21 and 28. Threshold shifts were calculated
for every single frequency and point in time by subtracting the
preoperative baseline CAP thresholds from the respective post-
operative results. For statistical analysis CAP threshold shifts were
grouped into low (0.5e2 kHz), middle (2.5e8 kHz) and high fre-
quencies (10e32 kHz).
2.3. Anesthesia
Hydrogel application as well as CI surgery was performed under
general anesthesia, using medetomidine (0.3 mg/kg), midazolam
(1 mg/kg), fentanyl (0.03 mg/kg) and ketamine (10 mg/kg). For CI
surgery, lidocaine (4 mg/kg) was used for local anesthesia. At the
end of the procedures, anesthesia was partially antagonized using
atipamezole (1 mg/kg) and ﬂumazenil (0.1 mg/kg). All guinea pigs
received carprofen (4 mg/kg) and enroﬂoxacin (7 mg/kg) before
surgery and once per day on the following 2 days. During CI surgery,
Fig. 1. Micrographs of mid-modiolar cross-sections through guinea pig cochleae.
Hematoxylin-eosin staining. (A) Illustration of the quadrants of the scala tympani for
the semiquantitative evaluation of apparent tissue response according to O'Leary et al.,
2013. The scala tympany (ST) was divided into 4 quadrants (Q1, Q2, Q3 and Q4). The
scala vestibuli (SV), ductus cochlearis (DC), basilar membrane (BM) and Rosenthal's
canal (RC) were labelled for better orientation. (B, C) Micrographs of Rosenthal's canal
in the lower turn of the cochlea of control (B) and Dex d-1 (C) animals. Density of spiral
ganglion cells (SGC) per area of Rosenthal's canal (RC) was reduced in Dex d-1 animals
compared to control animals. Scale bar (A) 100 mm and (B, C) 50 mm.
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to monitor physical condition. To maintain body temperature at
38 C, a heating plate was used when performing surgery or
hearing measurements.
2.4. Hydrogel preparation and application procedure
The 20% w/v POX407 hydrogel (BASF SE, Ludwigshafen, Ger-
many) was prepared using the cold technique (Engleder et al.,
2014). POX407 was slowly added to 10 mM PBS pH 7.4. After the
addition of 6% microcrystalline dexamethasone (Gatt-Koller,
Absam, Austria), the solution was stored at 4 C and resuspended
directly before use. Under visualization with an operating micro-
scope, the tympanic membrane was perforated in the superior
posterior quadrant and 50 ml of the hydrogel were applied to the
area of the round window niche using a YOU-1 micromanipulator
(Narishige, Tokyo, Japan) and Hamilton syringes (Hamilton, Bona-
duz, Switzerland) with blunt 29G needles (Honeder et al., 2015a).
2.5. Cochlear implant surgery
A custom-made, conically shaped silicone electrode with one
contact (MED-EL GmbH, Innsbruck, Austria) was used. The diam-
eter was 0.3 mm at the tip of the electrode and increased to a
diameter of 0.5 mm 4 mm from the tip. In general anesthesia, the
right postauricular area was shaved and prepared with povidone
iodine (“Betaisodona”, Mundipharma, Limburg, Germany).
Following the postauricular skin incision, the bulla was exposed
and opened using a number 15 scalpel. As the next step, a teﬂon-
insulated gold wire (Goodfellow, Bad Nauheim, Germany) was
attached to the bony ridge of the round window niche using his-
toacryl glue (Braun Melsungen, Melsungen, Germany) and preop-
erative CAP thresholds were determined before drilling a 0.8 mm
cochleostomy approximately 1 mm from the round window niche.
Then, the electrode was inserted 5 mm and the cochleostomy was
sealedwith amuscle graft. The transcutaneous pins of the electrode
were placed at the vertex of the animal using two 4 mm stainless
steel screws and denture resin (Paladur, Heraeus Kulzer, Hanau,
Germany), which was also used to close the bulla. Finally, the gold
wire was soldered to an additional pin to allow for future CAP
measurements and wounds were closed in two layers using 4-
0 Vicryl sutures (Ethicon, Norderstedt, Germany).
2.6. Histology
In deep general anesthesia, animals were perfused trans-
cardially with buffered paraformaldehyde (PFA 4%; Sigma Aldrich,
Seelze, Germany) before temporal bones were harvested. Tympanic
bullae were opened carefully and postﬁxed in buffered PFA for at
least 48 h. Subsequently, samples were randomly assigned to the
preparation of organ of Corti whole mounts or embedding,
sectioning and hematoxylin-eosin (H&E) staining. As one cochlea
per group was lost due to damage during harvesting or processing,
only 4 samples per group were available for the preparation of
organ of Corti whole mounts. In these cases, the bony capsule of the
cochlea was carefully removed from the ﬁxed specimens for the
preparation of organ of Corti whole mounts. Samples were stained
using phalloidin-tetramethylrhodamine B isothiocyanate (0.3 mg/
ml PBS; Phalloidin-TRITC; Sigma-Aldrich, Vienna, Austria) and
Hoechst 33342 trihydrochloride trihydrate (0.05 mg/ml PBS; Mo-
lecular Probes, Invitrogen Corp., Carlsbad, CA) for 30 min at room
temperature. After staining, each turn of the cochleawas separately
embedded in FluorSave reagent (Calbiochem, Darmstadt, Germany)
and at least ﬁve 200 mm sections per turn were evaluated for inner
hair cell (IHC) and outer hair cell (OHC) numbers by means ofconfocal microscopy (Honeder et al., 2015a). To allow for H&E
staining, 5 bullae per group were decalciﬁed in 8% ethyl-
enediaminetetraacetic acid until bony structures allowed trim-
ming. The demineralization facilitated the faultless removal of the
histoacryl glue and the electrode, without any secondary damage to
the samples. After embedding in parafﬁn, the preparation was cut
at a thickness of 4 mm and every ﬁfth section was stained with H&E
for morphologic evaluation. About thirty sections were evaluated
per specimen and representative sections were photographed un-
der a light microscope (Polyvar, Reichert-Jung, Vienna, Austria). To
describe the location and to allow a semi-quantitative evaluation of
the ﬁbrosis, scala tympani was divided into four quadrants, with
Q1 ¼ upper inner quadrant, Q2 ¼ upper outer quadrant,
Q3¼medio-inferior and Q4¼ latero-inferior quadrant according to
O'Leary et al. (Fig. 1A). Also osteoneogenesis was rated according to
O'Leary et al. as absent, minimal, and occupying less or more than
one quarter of the tissue response (O'Leary et al., 2013). Ellipse 3D
software (ViDiTo, Kosice, Slovakia) was used to count all nucleated
spiral ganglion cells (SGCs) in three mid-modiolar sections - each
separated by 25 mm - and to calculate the density by dividing the
number of SGC by the area of Rosenthal's canal (Fig. 1B and C). All
histopathological examinations were performed blinded to the
assigned treatment.
2.7. Calculations (Greenwood function)
According to the Greenwood function for guinea pigs:
F ¼ 0.35(10(2.1/18.5)x - 0.85) (Greenwood, 1990), the analyzed
frequency-groups tested for different effects of the electrode
insertion trauma (EIT). Taking into account the cochleostomy site
1 mm from the round window membrane and the insertion depth
of 5 mm, frequencies from 10 to 32 kHz represent the area directly
affected by the electrode insertion. Frequencies from 2 to 8 kHz
represent the area in proximity to, but not directly affected by the
CI-electrode, whereas the lowest frequencies from 0.5 to 2 kHz
represent the cochlear apex.
2.8. Statistics
Data points represent mean values. Error bars represent SD or
SEM as indicated below the respective ﬁgure. Data analysis was
performed using IBM SPSS Statistics version 23 (IBM Corp.,Armonk,
NY). Statistical analysis was performed using one-way ANOVA and
Tukey's HSD for post-hoc analysis.
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3.1. Compound action potentials
The insertion of the CI-electrodes resulted in pronounced CAP
threshold shifts in all frequency groups (Fig. 2). In the low fre-
quencies (0.5e2 kHz), which represent the most apical part of the
cochlea, postoperative threshold shifts in the Dex d-7 group
(35.2 dB) were signiﬁcantly higher than in the Dex d-1 (26.1 dB)
and the control group (28.8 dB). Threshold shifts in the Dex d-1
group showed a higher rate of recovery and were signiﬁcantly
lower than in the other groups at days 21 and 28. Low-frequency
threshold shifts on day 28 were 14.2 dB, 23.1 dB, and 23.3 dB in
the Dex d-1, the Dex d-7, and the control group, respectively
(Fig. 2A). In the middle frequencies (2.5e8 kHz), which representFig. 2. CAP threshold shifts at A) low, B) middle, and C) high frequencies. Symbols
indicate p < 0.05. *: Dex d-1 vs control & Dex d-7; þ: control vs Dex d-7; x:Dex d-1 vs
Dex d-7. Error bars indicate SEM.the area apical to the tip of the electrode, threshold shifts in the Dex
d-1 group were signiﬁcantly lower than in the other groups at all
points in time. Additionally, a signiﬁcant difference between the
Dex d-7 group and the control group was found immediately after
surgery, but resolved by day 3. In this frequency range, mean
threshold shifts on day 28 were 24.8 dB, 36.6 dB, and 35.9 dB, for
the Dex d-1, the Dex d-7, and the control group, respectively.
(Fig. 2B). CAP threshold shifts were most pronounced in the high
frequency range (10e32 kHz), which represents the basal part of
the cochlea (Fig. 2C). This portion of the inner ear is implantedwith,
and thereby directly affected by the CI-electrode. In these fre-
quencies, postoperative threshold shifts were also signiﬁcantly
smaller in the Dex d-1 group (30.3 dB) as compared to the Dex d-7
group (53.7 dB), and the control group (51.4 dB). Over the time
course of 4 weeks, threshold shifts decreased slightly to 20.2 dB,
42.6 dB, and 41.0 dB, in the Dex d-1, the Dex d-7, and the control
group, respectively. Compared to the Dex d-7 group and the control
group, animals in the Dex d-1 group showed signiﬁcantly lower
threshold shifts at all points in time (Fig. 2C).
3.2. Organ of Corti whole mounts
Hair cell counts were evaluated in the middle and apical part of
the cochlea and are presented as the average number of IHCs and
OHCs per 200 mm section of the organ of Corti. Due to the EIT and
the associated ﬁbrosis we were unable to perform meaningful hair
cell counts in the basal turn of the cochlea. In the middle turn of the
cochlea, IHCs were almost completely preserved and OHCs were
partially lost, but no statistically signiﬁcant difference between the
experimental groups was found (Fig. 3A and B). IHCs were intact in
the apical area of the cochlea in all treatment groups. In this area, a
signiﬁcantly higher number of OHCs was found in the Dex d-1
group as compared to the control group (Fig. 3A and B).
3.3. H&E stainings
The histopathological examination revealed a relatively trau-
matic electrode insertion and showed a fracture of the osseous
spiral lamina as well as an electrode dislocation into scala vestibuli
in 80% of Dex d-1, 40% of Dex d-7 and 20% of control animals
(Table 1). Fibrosis and osteoneogenesis were evaluated on the
section with the largest cochleostomy diameter, as well as on mid-
modiolar sections. Both, ﬁbrosis and osteoneogenesis were present
in all cochleostomy sections and were associated with the EIT.
Histopathological ﬁndings in the scala tympani of the basal turn,
which were evaluated in the mid-modiolar sections are summa-
rized in Tables 1 and 2. In these sections, the amount of ﬁbrosis and
osteoneogenesis appeared to correlate with the EIT and electrode
translocation. SGC quantiﬁcation revealed a signiﬁcantly lower
SGC-density in the lower turn of the cochlea of Dex d-1 animals, a
slightly, but signiﬁcantly reduced number of SGCs in the middle
turn and no signiﬁcant differences in the apical turn of the cochlea
(Table 3).
4. Discussion
Despite the evaluation of different GC delivery protocols, it re-
mains unclear until today which mode (systemic or topical) and
timing of application yields the most favorable outcomes
(Eastwood et al., 2010; James et al., 2008; Kuthubutheen et al.,
2015; Lee et al., 2013). The aim of this study was to shed light on
these important questions.
Preoperative GC administration is a promising strategy to
improve outcomes in hearing preservation CI because it allows the
ear to prepare for the upcoming insult of electrode insertion.
Fig. 3. Number of A) IHCs and B) OHCs per 200 mm section of the organ of Corti. The
2nd turn and the apical turn of the cochlea were analyzed separately. A signiﬁcantly
higher number of OHCs was found in the cochlear apex after application of dexa-
methasone 1 day prior to CI. * p < 0.05. Error bars represent SD.
Table 3
Spiral ganglion cell densities (cells/mm2 ± SD) at different locations.
Basal turn Middle turn Apical turn
Control 1187.0 ± 75.5 1520.7 ± 50.7 1530.7 ± 60.9
Dex d-1 665.7 ± 89.4a 1318.1 ± 55.1b 1326.9 ± 173.8
Dex d-7 1169.6 ± 83.8 1470.0 ± 47.0 1265.0 ± 55.0
a ANOVA, p < 0.05 compared to control and Dex d-7.
b ANOVA, p < 0.05 compared to control.
C. Honeder et al. / Hearing Research 341 (2016) 43e49 47Different delivery protocols have been evaluated, but so far it is
unclear whether systemic or topical application provides better
protection. The time required for the transcriptional effects of GCs
as well as results from studies directly addressing hearing loss after
CI suggest a potential beneﬁt of early GC application (Chang et al.,
2009; Kuthubutheen et al., 2015). Preoperative exposure time is
even more important when the aim is to reach more apical parts of
cochlea, because the distribution of GCs in the inner ear is based on
diffusion (Plontke et al., 2008). Until now, prolonged topical GC
application was not easily feasible and associated with repeated IT
injections or the implantation of devices allowing a sustained de-
livery (Plontke et al., 2009). These challenges can be overcome by
using POX407 as drug delivery device, which is easily applicableTable 1
Histopathology I: Electrode translocation and osteoneogenesis.
Electrode translocation Osteoneogenesis absent Osteon
Control 20% (1/5) 60% (3/5) 20% (1
Dex d-1 80% (4/5) 0% (0/5) 0% (0/
Dex d-7 40% (2/5) 0% (0/5) 80% (4
Table 2
Histopathology II: Fibrosis.
Fibrosis absent Fibrosis in one quadrant Fibrosis in tw
Control 20% (1/5) 40% (2/5) 20% (1/5)
Dex d-1 0% (0/5) 0% (0/5) 40% (2/5)
Dex d-7 0% (0/5) 20% (1/5) 40% (2/5)and results in a long-term release of GCs to the inner ear with peak
concentrations during the ﬁrst day after application (Honeder et al.,
2014; Piu et al., 2011).
Interestingly, in our study we found a protective effect of the
dexamethasone hydrogel only if it was applied one day prior to CI,
which makes us speculate that high perilymph concentrations
during electrode insertion are important to achieve otoprotection.
In contrast to many previous studies, we were able to show a
protection of low frequency hearing after 28 days (Connolly et al.,
2011; James et al., 2008; Kuthubutheen et al., 2015). The signiﬁ-
cantly reduced hearing threshold shifts in the low frequencies after
one month, without a signiﬁcant difference immediately after
surgery and the higher number of OHCs in the apical part of the
cochlea hint at potential long-term effects of a single preoperative
GC dose. Similar effects have also been described for a single
perioperative administration of triamcinolone-acetonide directly
into the inner ear (Braun et al., 2011). Even though this result is very
promising, it has to be interpretedwith caution because the volume
of the guinea pig cochlea differs considerably from the human inner
ear, and in contrast to the human cochlea, the bone of the guinea
pig cochlear wall is relatively thin, which allows drugs to enter
through the cochlear apex (Mikulec et al., 2009). This could result in
signiﬁcantly different apical GC-concentrations in humans and
potentially cause a reduction of the otoprotective effects. In an
attempt to overcome this ﬂaw of the guinea pig model, the POX407
solution was applied directly to the round window region, where it
quickly solidiﬁed into a hydrogel. Therefore, unwanted apical
resorption of the GC was minimized. Dexamethasone application
one day prior to surgery resulted in reduced postoperative CAP
threshold shifts in the middle and high frequencies, which are
directly affected by the electrode insertion. Surprisingly, we found a
reduced number of SGCs in basal and middle turn of the Dex d-1
animals, which is in contrast to the improved hearing outcomes.
The loss of SGCs - especially in the basal turn e could be associated
with the greater amount of EIT, particularly electrode translocation
into the scala vestibuli, which was more frequent in the Dex d-1
(80%) than in the control group (20%). This relatively high insertion
trauma is a minor drawback of the study, as it makes the compar-
ison of the obtained results to clinical EAS cases, which areeogenesis minimal Osteoneogenesis <25% Osteoneogenesis >25%
/5) 20% (1/5) 0% (0/5)
5) 80% (4/5) 20% (1/5)
/5) 20% (1/5) 0% (0/5)
o quadrants Fibrosis in three quadrants Fibrosis in all quadrants
0% (0/5) 20% (1/5)
40% (2/5) 20% (1/5)
40% (2/5) 0% (0/5)
C. Honeder et al. / Hearing Research 341 (2016) 43e4948implanted using the “soft surgery” technique, and also to other
guinea pig studies, which usually reported lower hearing threshold
shifts and electrode translocation rates, more difﬁcult (Chang et al.,
2009; Kuthubutheen et al., 2015; O'Leary et al., 2013). As only half
of the samples were randomized to histopathology, it is possible
that an analysis of all samples would have had a leveling effect on
the differing electrode translocation rates. A neurotoxic effect of the
hydrogel is unlikely, as no SGC loss was found in the Dex d-7 group.
GC receptors have been detected in many parts of the cochlea,
including the spiral ganglion (ten Cate et al., 1993). As GCs could
directly inﬂuence SGC function, it is important to state that the SGC
count is not a measure of SGC function, but only of histological
appearance. An altered SGC function after GC application is a po-
tential explanation for the diverging results in hearing threshold
shifts and SGC counts and should be addressed in future studies.
The protective effects of preoperative topical GC application
demonstrated in this study and the recently described auditory
beneﬁts of dexamethasone-eluting electrodes make it tempting to
speculate about potential synergistic effects of these two strategies
(Bas et al., 2016). The preoperative application could prepare the
cochlea for the acute EIT and thereby reduce postoperative hearing
threshold shifts, and the drug-eluting electrode could counteract
hearing loss, foreign body reaction, and increases in impedances in
the long term.
5. Conclusions
Preoperative IT dexamethasone hydrogels can reduce EIT-
induced hearing threshold shifts at low, middle and high fre-
quencies. As this application protocol preserved the clinically
relevant low-frequency hearing after CI, the ﬁndings described
herein might have an important impact in the clinical practice. As
POX407 hydrogels will most likely be available for physicians in the
near future, this strategy should be evaluated in clinical studies.
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